David DeNardo, PhD

David DeNardo

Researcher Background

Primary Academic Title

Professor; Section Co-Director - Molecular Oncology

Education

  • 1999: BS in Biology, Willamette University, Salem, OR
  • 2005: PhD in Cell Biology, Baylor College of Medicine, Houston, TX
  • 2010: Postdoctoral Scholar, Department of Pathology, University of California, San Francisco, CA

Research & Selected Publications

Research Interest

Immune response, metastasis, breast cancer, and pancreatic cancer

Research Publications

Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic.
Authors:

Somani VK, Zhang X, Chen TH, one or more additional authors omitted DeNardo DG, one or more additional authors omitted Lim KH

Journal & Year:

Mol Cancer • 2026

Chemotherapy-induced adipo-lineage cell senescence drives bone loss.
Authors:

Raut GK, Malachowski T, Melam A, one or more additional authors omitted DeNardo DG, Stewart SA

Journal & Year:

Nat Commun • 2025

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.
Authors:

Grierson PM, Wolf C, Suresh R, one or more additional authors omitted DeNardo DG, Lim KH

Journal & Year:

Clin Cancer Res • 2025

Human interpretable grammar encodes multicellular systems biology models to democratize virtual cell laboratories.
Authors:

Johnson JAI, Bergman DR, Rocha HL, one or more additional authors omitted DeNardo DG, one or more additional authors omitted Macklin P

Journal & Year:

Cell • 2025

Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer.
Authors:

Hogg GD, Weinstein AG, Kingston NL, one or more additional authors omitted DeNardo DG

Journal & Year:

Sci Immunol • 2025

HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.
Authors:

Yamamoto N, Dobersch S, Loveless I, one or more additional authors omitted DeNardo DG, one or more additional authors omitted Kugel S

Journal & Year:

Clin Cancer Res • 2025

Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity.
Authors:

Hänggi K, Li J, Gangadharan A, one or more additional authors omitted DeNardo DG, one or more additional authors omitted Ruffell B

Journal & Year:

Cancer Cell • 2024

Targeting dendritic cells to drive PDAC immunotherapy response.
Authors:

Weinstein AG, DeNardo DG

Journal & Year:

Trends Pharmacol Sci • 2024